Profitability Ratios
| Ratio |
Value |
| GP Margin |
81.1% |
| EBIT Margin |
19.2% |
| EBITDA Margin |
28.6% |
| Operating Margin |
18.5% |
| Pretax Margin |
16.1% |
| Cont. Ops Margin |
13.0% |
| Net Margin |
13.0% |
| Bottom Line Margin |
13.0% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
0.93 |
| Quick Ratio |
0.74 |
| Solvency Ratio |
0.192 |
| Cash Ratio |
0.20 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
28.87 |
| PEG Ratio |
-0.71 |
| Forward PEG |
-0.71 |
| Price/Book |
4.98 |
| Price/Sales |
3.76 |
| Price/FCF |
27.92 |
| Price/Op Cash Flow |
17.12 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.2895 |
| Debt/Equity |
0.7383 |
| Debt/Capital |
0.4247 |
| Long-Term Debt/Capital |
0.3939 |
| Financial Leverage |
2.55 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
-14.37 |
| Operating Cash Flow Ratio |
0.426 |
| Operating Cash Flow/Sales |
21.9% |
| Free Cash Flow/Operating Cash Flow |
61.3% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
3.59 |
| Interest Coverage |
5.9471 |
| Short-Term Operating Cash Flow Coverage |
5.50 |
| Operating Cash Flow Coverage |
0.39 |
| Capital Expenditure Coverage |
2.59 |
| Dividend + Capital Expenditure Coverage |
1.29 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
65.7996% |
| Dividend Yield |
2.2790% |
| Dividend Yield % |
2.2790% |
| Dividend Per Share |
1.4932 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
17.44 |
| EPS |
2.269 |
| Debt/Share |
10.2568 |
| Cash/Share |
1.78 |
| Book Value/Share |
13.18 |
| Tangible BV/Share |
-5.59 |
| Equity/Share |
13.16 |
| Operating Cash Flow/Share |
3.826 |
| Capital Expenditure/Share |
1.479 |
| FCF/Share |
2.347 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
0.809 |
| Earnings Before Tax/EBIT |
0.869 |
| Price/Fair Value |
4.98 |
| Debt/Market Cap |
0.1411 |
| Effective Tax Rate |
19.0% |
| Enterprise Value Multiple |
14.75 |
AZN - AstraZeneca PLC